Business Wire

FONDATION-IPSEN

26.11.2015 15:01:22 CET | Business Wire | Press release

Share
The 2015 Fondation IPSEN Longevity Prize Has Been Awarded to Steven N. Austad

The 20th annual Longevity Prize of the Fondation IPSEN has been awarded to Steven N. Austad (University of Alabama at Birmingham, USA ), in recognition of his outstanding leadership in the domain of the comparative biology of aging (especially the study of species resisting to aging), by an international jury led by Thomas Kirkwood (Newcastle University, Newcastle, UK ). He received the €20,000 prize on November 21st , 2015 at the Gerontology Society of America (GSA) in Orlando, USA where he presented an outstanding lecture.

“Evolution is smarter than you are.” That quote from biochemist Leslie Orgel forms the basis for looking to nature for creative ways to slow the damaging processes of aging. Ironically, the laboratory animals scientists generally use to try to understand aging processes – and learn how to retard them – are demonstrably unsuccessful at combating these degenerative processes. It doesn’t take long to determine whether the researchers have succeeded in lengthening their health- and lifespan. On the other hand, methods for making an animal that normally lives 2 years survive to age 4, may not be relevant for an animal – humans – that already lives 80 years or more. A complementary approach is to scour nature for animals that nature has already given the tools to combat aging successfully and to try to discover what those tools are and how they work. Animals that are more successful than humans at resisting aging processes are abundant on earth. The research of Steven N. Austad has employed a number of such species over the years.

Dr. Austad is Distinguished Professor and Chair of the Department of Biology at the University of Alabama at Birmingham and also Scientific Director of the American Federation for Aging Research. After receiving his PhD degree from Purdue University, he accepted his first faculty position as Assistant Professor at Harvard University in 1986. He subsequently moved to the University of Idaho where he became full professor in 1997. In 2004, he joined the Barshop Institute for Longevity & Aging Studies at the University of Texas Health Science Center San Antonio in San Antonio, Texas before moving to his current position in 2014. His research encompasses many aspects of the biology of aging from the molecular to the population level. His research specialty is the identification and study of nontraditional species – particularly exceptionally long-lived species – for insight into processes of slow aging. Dr. Austad’s research has won multiple previous awards, including the Geron Corporation-Samuel Goldstein Distinguished Publication Award, the Nathan A. Shock Award, the Robert W. Kleemeier Award, the Purdue Outstanding Alumnus Award, and the Irving S. Wright Award of Distinction.

Previous laureates of the Longevity Prize
Founded in 1996, the Longevity Prize of the Fondation IPSEN has been awarded to renowned specialists: Caleb E. Finch (Los Angeles, 1996) , Vaino Kannisto (Lisboa, 1997), Roy L. Walford (Los Angeles, 1998), John Morley (St Louis,1999), Paul & Margret Baltes (Berlin, 2000), Justin Congdon (Aiken, 2001), George Martin (Seattle, 2002), James Vaupel (Rostock, 2003), Linda Partridge (London, 2004), Sir Michael Marmot (London, 2005), Cynthia Kenyon (San Francisco, 2006), David Barker (Southampton, 2007), Gerald McLearn (University Park, 2008 ), Jacques Vallin (Paris, 2009), Judith Campisi (Novato, 2010), Tom Kirkwood (Newcastle, 2011), Linda Fried (New York, 2012), Gary Ruvkun (Boston, 2013), Luigi Ferrucci (Baltimore, 2014).

The jury members of the Longevity Prize
Thomas Kirkwood (Newcastle University, Newcastle, UK ), President
Judith Campisi (Buck Institute for Research on Ageing, Novato, USA ), Eileen Crimmins (University of Southern California, Los Angeles, USA ), Caleb Finch (University of Southern California, Los Angeles, USA ), Bernard Jeune (Odense Universitet, Odense, Denmark ), George Martin (University of Washington, Seattle, USA ), Jean-Marie Robine (INSERM, Démographie et Santé, Montpellier, France ), Bruno Vellas (Hôpital Purpan, Toulouse, France ) and a Fondation IPSEN representative.

About the Fondation IPSEN
Established in 1983 under the aegis of the Fondation de France, the mission of the Fondation IPSEN is to contribute to the development and dissemination of scientific knowledge. The long-standing action of the Fondation IPSEN aims at fostering the interaction between researchers and clinical practitioners, which is essential due to the extreme specialization of these professions. The ambition of the Fondation IPSEN is to initiate a reflection about the major scientific issues of the forthcoming years. It has developed an important international network of scientific experts who meet regularly at meetings known as Colloques Médecine et Recherche , dedicated to six main themes: Alzheimer's disease, neurosciences, longevity, endocrinology, the vascular system and cancer science. Moreover the Fondation IPSEN has started since 2007 several meetings in partnership with the Salk Institute, the Karolinska Institutet, the Massachusetts General Hospital, the Days of Molecular Medicine Global Foundation as well as with the science journals Nature , Cell and Science . The Fondation IPSEN produced several hundred publications; more than 250 scientists and biomedical researchers have been awarded prizes and research grants.
www.fondation-ipsen.org

Contact:

Image Sept
Isabelle de Segonzac, Tel: +33 (0)1 53 70 74 70
Email: isegonzac@image7.fr

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings7.8.2026 19:48:00 CEST | Press release

An ICC Arbitral Tribunal has awarded AOP Orphan Pharmaceuticals GmbH (“AOP Health”) a total of about EUR 112 Mio in a quantum award issued in the ongoing arbitration proceedings with PharmaEssentia Corp. (“PharmaEssentia”) concerning BESREMi® (ropeginterferon alfa-2b). The award quantifies AOP Health’s damage claims for PharmaEssentia’s intentional breaches at ca. EUR 82 Mio. It also awards AOP Health ca. EUR 31 Mio plus interest as reimbursement for AOP Health overpayments made to PharmaEssentia as a result of excessive pricing in the years 2019-2022. The Tribunal thereby confirmed that PharmaEssentia has been overcharging AOP Health by up to 900% over these years. The Tribunal affirmed AOP Health's valid set-off of the profit-sharing payments amount owed to PharmaEssentia of approximately EUR 17 Mio against AOP Health's substantially exceeding damages claims. This means that AOP Health shall not make any payment to PharmaEssentia. Interest on AOP Health’s claims will continue to accr

Coulson Aviation Canada Acquires 10 Former RCAF Hercules, Doubling C-130H Fleet7.8.2026 19:16:00 CEST | Press release

Canadian-led expansion will build the world’s largest and most capable C-130 airtanker fleet Coulson Aviation Canada, the Canadian division of Coulson Aviation, has acquired 10 former Royal Canadian Air Force CC-130H Hercules aircraft from the Government of Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260807019094/en/ Britton Coulson, left, and Wayne Coulson stand in front of one of 10 former Royal Canadian Air Force CC-130H Hercules aircraft recently acquired by Coulson Aviation from the Government of Canada. At right is a Coulson C-130H outfitted for aerial firefighting with the company’s proprietary RADS-XXL retardant delivery system, capable of carrying up to 4,000 U.S. gallons, or more than 15,000 litres, of water or fire retardant. The acquisition doubles Coulson’s global C-130H fleet to 20 aircraft, expanding its capacity to build the world’s largest C-130 airtanker fleet. The acquisition doubles Coulson’s g

Energy Vault Announces Strategic Agreement to Deploy 1.25 GW of Integrated Power Infrastructure for Hyperscaler AI Data Center with Leading Power Generation EPC Deploying Caterpillar Gensets7.8.2026 18:16:00 CEST | Press release

Partnership combines Energy Vault's FEOC-compliant BESS, grid-forming PCS, and AI infrastructure control software with partner’s turnkey power generation, Caterpillar gensets and EPC capabilitiesReference architecture delivers firm grid-independent power, essential grid stabilization and load balancing to deliver modular, scalable, gigawatt-scale AI campuses with "always-on" availabilitySecond strategic framework agreement together advances Energy Vault's AI infrastructure strategy and establishes a repeatable “speed-to-power” deployment platformInitial 1.25 GW is backed by a hyperscaler customer contract for deployment in TexasEnergy Vault expects a revenue impact of ~$500 - $600 million in 2H 2026 and 2027, which will be discussed during the upcoming earnings call on August 11, 2026 Energy Vault Holdings, Inc. (NYSE: NRGV) ("Energy Vault"), a global leader in sustainable energy infrastructure, today announced the execution of a strategic commercial agreement under which Energy Vault

SES Advances Next-generation MEO Strategy Following Successful Completion of IRIS² Rendez-vous 17.8.2026 10:52:00 CEST | Press release

IRIS² expands SES's differentiated MEO architecture while supporting Europe's secure, sovereign multi-orbit connectivity ambitions SES today announced the successful completion of Rendez-vous 1 (RDV1) under the Infrastructure for Resilience, Interconnectivity and Security by Satellite (IRIS²) programme, marking a key milestone in the programme's implementation phase and reinforcing Europe's path towards sovereign, resilient and secure satellite connectivity. The successful completion of RDV1 confirms the programme's readiness to move forward with implementation and provides greater visibility on the long-term scope, performance and economics of the MEO segment. SES's expected capital commitment for the MEO segment is up to €1.35 billion, reflecting current programme scope, while maintaining the deployment of 18 MEO satellites and the targeted service entry in 2030. SES’s share of the investment in the IRIS² programme for 2026 is included in SES’s FY26 Capex outlook as previously commun

Allianz Delivers Record Result and Is Well on Track to Achieve Its Targets7.8.2026 07:10:00 CEST | Press release

2Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806509750/en/ Oliver Bäte, Chief Executive Officer of Allianz SETotal business volume at 45.6 billion euros, an internal growth of 5.7 percent1, with contributions from all segments. Asset Management delivers excellent growth. Operating profit rises 10.6 percent to a record level of 4.9 billion euros. Shareholders’ core net income at 2.6 billion euros; 12.7 percent below last year. Adjusted for a divestment gain last year and offsetting measures following the sale of the stake in our Indian JVs, underlying growth is strong at 10 percent. 6M 2026Total business volume at 98.6 billion euros, an internal growth of 4.3 percent1, driven by Property-Casualty and especially Asset Management. Operating profit rises 8.6 percent and reaches a record level of 9.4 billion euros. Shareholders’ core net income advances 15.5 percent to 6.4 billion euros. Adjusted for divestment effec

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye